Incyte and Novartis settle Jakafi royalty dispute with a $280M payment and future royalty rate cuts. Read more here.

Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an ...

New research disentangles the risks for acute kidney injury related to CAR T-cell treatment in non-Hodgkin lymphoma, ...

The main focus of the deal is undoubtedly pelabresib, which was combined with Novartis/Incyte’s JAK inhibitor Jakafi (ruxolitinib), a standard first-line therapy for MF, in the phase 3 MANIFEST ...

Incyte and Morphosys’ Monjuvi antibody therapy ... for acute lymphoblastic leukaemia (ALL), as well as two CAR-T therapies – Novartis’ Kymriah (tisagenlecleucel) and Gilead’s Yescarta ...

Improvements in Scalp Itch-Numeric Rating Scale (SI-NRS) were greater in the roflumilast group than for the vehicle group, ...

Shares of Incyte Corp. INCY rallied 3.17% to $60.85 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 3.26% to 5,844.19 and ...

Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

LONDON, May 12 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health ...

Icotrokinra demonstrated high rates of clearance in scalp and genital psoriasis after 16 weeks of treatment, according to ...

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told ...